{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:38:51Z","timestamp":1791722331974,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"DOI":"10.7759\/cureus.95288","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:37:16Z","timestamp":1761295036000},"source":"Crossref","is-referenced-by-count":6,"title":["Emerging Perspectives in the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Narrative Review"],"prefix":"10.7759","author":[{"given":"Albine","family":"Djeagou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavyasri","family":"Gunukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Sermani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Kiran","family":"Vaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-242","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"113","author":"Cataldo I","year":"2021","unstructured":"Cataldo I, Sarcognato S, Sacchi D, et al.. Pathology of non-alcoholic fatty liver disease. Pathologica. 2021, 113:194-202. 10.32074\/1591-951X-242","journal-title":"Pathologica"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza S","year":"2021","unstructured":"Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Biosci (Landmark Ed). 2021, 26:206-37. 10.2741\/4892","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2014.00004","article-title":"Knowing what\u2019s out there: awareness of non-alcoholic fatty liver disease","volume":"1","author":"Ghevariya V","year":"2014","unstructured":"Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J, Anand S. Knowing what\u2019s out there: awareness of non-alcoholic fatty liver disease. Front Med (Lausanne). 2014, 1:4. 10.3389\/fmed.2014.00004","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4137\/cmt.s18885","article-title":"Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options","volume":"8","author":"Banini BA","year":"2016","unstructured":"Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016, 8:75-84. 10.4137\/cmt.s18885","journal-title":"Clin Med Insights Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi K","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al.. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022, 7:851-61. 10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr RM","year":"2016","unstructured":"Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016, 45:639-52. 10.1016\/j.gtc.2016.07.003","journal-title":"Gastroenterol Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander C","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023, 119:1787-98. 10.1093\/cvr\/cvad095","journal-title":"Cardiovasc Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122082","article-title":"Pathophysiology of non alcoholic fatty liver disease","volume":"17","author":"Petta S","year":"2016","unstructured":"Petta S, Gastaldelli A, Rebelos E, et al.. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci. 2016, 17:2082. 10.3390\/ijms17122082","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i43.16079","article-title":"Gut microbiota and metabolic syndrome","volume":"20","author":"Festi D","year":"2014","unstructured":"Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014, 20:16079-94. 10.3748\/wjg.v20.i43.16079","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino G","year":"2020","unstructured":"Carpino G, Del Ben M, Pastori D, et al.. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology. 2020, 72:470-85. 10.1002\/hep.31056","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432007","article-title":"Cytokines in alcoholic and nonalcoholic steatohepatitis","volume":"343","author":"Tilg H","year":"2000","unstructured":"Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000, 343:1467-76. 10.1056\/NEJM200011163432007","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100444","article-title":"Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators","volume":"4","author":"Pastore M","year":"2022","unstructured":"Pastore M, Caligiuri A, Raggi C, et al.. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Rep. 2022, 4:100444. 10.1016\/j.jhepr.2022.100444","journal-title":"JHEP Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2011.219691","article-title":"Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut","volume":"590","author":"Seki E","year":"2012","unstructured":"Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012, 590:447-58. 10.1113\/jphysiol.2011.219691","journal-title":"J Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.047","article-title":"Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease","volume":"145","author":"Murphy SK","year":"2013","unstructured":"Murphy SK, Yang H, Moylan CA, et al.. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013, 145:1076-87. 10.1053\/j.gastro.2013.07.047","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032844","article-title":"Advances in the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"24","author":"Yin X","year":"2023","unstructured":"Yin X, Guo X, Liu Z, Wang J. Advances in the diagnosis and treatment of non-alcoholic fatty liver disease. Int J Mol Sci. 2023, 24:2844. 10.3390\/ijms24032844","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice","volume":"25","author":"Zhou JH","year":"2019","unstructured":"Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019, 25:1307-26. 10.3748\/wjg.v25.i11.1307","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i39.11077","article-title":"Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance","volume":"21","author":"St\u00e5l P","year":"2015","unstructured":"St\u00e5l P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol. 2015, 21:11077-87. 10.3748\/wjg.v21.i39.11077","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12068","article-title":"Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease","volume":"78","author":"Kalveram L","year":"2024","unstructured":"Kalveram L, Baumann U, De Bruyne R, et al.. Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease. J Pediatr Gastroenterol Nutr. 2024, 78:27-35. 10.1002\/jpn3.12068","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera L","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019, 156:1264-1281.e4. 10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee SS","year":"2014","unstructured":"Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:7392-402. 10.3748\/wjg.v20.i23.7392","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0011","article-title":"Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis","volume":"43","author":"Lee YH","year":"2019","unstructured":"Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019, 43:31-45. 10.4093\/dmj.2019.0011","journal-title":"Diabetes Metab J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12491","article-title":"Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease","volume":"12","author":"Li J","year":"2024","unstructured":"Li J, Delamarre A, Wong VW, de L\u00e9dinghen V. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease. United European Gastroenterol J. 2024, 12:219-25. 10.1002\/ueg2.12491","journal-title":"United European Gastroenterol J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi Y","year":"2014","unstructured":"Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014, 20:15539-48. 10.3748\/wjg.v20.i42.15539","journal-title":"World J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/nu11123064","article-title":"Evaluation of dietary approaches for the treatment of non-alcoholic fatty liver disease: a systematic review","volume":"11","author":"Saeed N","year":"2019","unstructured":"Saeed N, Nadeau B, Shannon C, Tincopa M. Evaluation of dietary approaches for the treatment of non-alcoholic fatty liver disease: a systematic review. Nutrients. 2019, 11:3064. 10.3390\/nu11123064","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni S","year":"2018","unstructured":"Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018, 24:3361-73. 10.3748\/wjg.v24.i30.3361","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/nu5082901","article-title":"Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease","volume":"5","author":"Simopoulos AP","year":"2013","unstructured":"Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients. 2013, 5:2901-23. 10.3390\/nu5082901","journal-title":"Nutrients"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i36.6549","article-title":"Treatment options for alcoholic and non-alcoholic fatty liver disease: a review","volume":"23","author":"Singh S","year":"2017","unstructured":"Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol. 2017, 23:6549-70. 10.3748\/wjg.v23.i36.6549","journal-title":"World J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet Lond Engl. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet Lond Engl"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs Daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs Daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. JAMA. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani S","year":"2024","unstructured":"Abdelgani S, Khattab A, Adams J, et al.. Empagliflozin reduces liver fat in individuals with and without diabetes. Diabetes Care. 2024, 47:668-75. 10.2337\/dc23-1646","journal-title":"Diabetes Care"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda C","year":"2008","unstructured":"Fern\u00e1ndez-Miranda C, P\u00e9rez-Carreras M, Colina F, L\u00f3pez-Alonso G, Vargas C, Sol\u00eds-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008, 40:200-5. 10.1016\/j.dld.2007.10.002","journal-title":"Dig Liver Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat A","year":"2020","unstructured":"Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells. 2020, 9:1638. 10.3390\/cells9071638","journal-title":"Cells"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15131","article-title":"Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis","volume":"36","author":"Gurka MJ","year":"2021","unstructured":"Gurka MJ, Mack JA, Chi X, DeBoer MD. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021, 36:249-56. 10.1111\/jgh.15131","journal-title":"J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen J","year":"2025","unstructured":"Armisen J, Rauschecker M, Sarv J, et al.. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J Hepatol. 2025, 83:31-42. 10.1016\/j.jhep.2024.12.046","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome PN","year":"2020","unstructured":"Newsome PN, Palmer M, Freilich B, et al.. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. J Hepatol. 2020, 73:231-40. 10.1016\/j.jhep.2020.03.024","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan PN","year":"2023","unstructured":"Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nat Rev Gastroenterol Hepatol. 2023, 20:679-88. 10.1038\/s41575-023-00796-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.06.008","article-title":"Fibroscan-AST (FAST) score for nonalcoholic steatohepatitis - validation in an Indian cohort","volume":"12","author":"De A","year":"2022","unstructured":"De A, Keisham A, Mishra S, et al.. Fibroscan-AST (FAST) score for nonalcoholic steatohepatitis - validation in an Indian cohort. J Clin Exp Hepatol. 2022, 12:440-7. 10.1016\/j.jceh.2021.06.008","journal-title":"J Clin Exp Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16513","article-title":"PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease","volume":"54","author":"Madsen BS","year":"2021","unstructured":"Madsen BS, Thiele M, Detlefsen S, et al.. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. Aliment Pharmacol Ther. 2021, 54:699-708. 10.1111\/apt.16513","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"Aga clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril JJ","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. Aga clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023, 165:1080-8. 10.1053\/j.gastro.2023.06.013","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/345592-emerging-perspectives-in-the-diagnosis-and-management-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:37:16Z","timestamp":1761295036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/345592-emerging-perspectives-in-the-diagnosis-and-management-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.95288","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}